Pre-hydration in cisplatin-based CCRT: Effects on tumour concentrations and treatment outcome

Aalbersberg, Else A.; Rossi, Maddalena; Veen, Linda J. de Wit – van der; Walraven, Iris; Heuvel, Michel M. van den; Sonke, Jan‐Jakob; Belderbos, J.; Vogel, Wouter V.

doi:10.1016/j.radonc.2019.01.015

Cited by 6 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The investigators treated the patients with CDDP and demonstrated that pre-hydration does not impair the therapeutic effect of CDDP in NSCLC patients. 112…”

Section: Current Strategies For Nephroprotection During Cddp Chemothe...mentioning

confidence: 99%

“…The investigators treated the patients with CDDP and demonstrated that pre-hydration does not impair the therapeutic effect of CDDP in NSCLC patients. 112 3.2.2 Comparison of long-duration hydration and shortduration hydration. Because patients with cancer and other diseases often experience a decline in immunity, renal function may be impaired due to their underlying disease.…”

Section: Food and Function Reviewmentioning

confidence: 99%

See 1 more Smart Citation

Protective effect of food derived nutrients on cisplatin nephrotoxicity and its mechanism

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The investigators treated the patients with CDDP and demonstrated that pre-hydration does not impair the therapeutic effect of CDDP in NSCLC patients. 112…”

Section: Current Strategies For Nephroprotection During Cddp Chemothe...mentioning

confidence: 99%

Section: Food and Function Reviewmentioning

confidence: 99%

Protective effect of food derived nutrients on cisplatin nephrotoxicity and its mechanism

et al. 2022

View full text Add to dashboard Cite

show abstract

“…5 Other studies conducted on the effect of short versus long hydration schemes have the same limitation as HYCIS1. [5][6][7][8][9][10][11][12][13][14][15] In order to inventorize the different cisplatin hydration schemes used in Dutch hospitals, we sent a survey to Dutch hospital pharmacies. Results of this survey showed that the cisplatin hydration schemes vary widely among hospitals and even within hospitals, depending on the indication and concomitant chemotherapy medication.…”

Section: What Is K Nown and Objec Tivementioning

confidence: 99%

“…Change in estimated glomerular filtration rate [Correction added on 01 September 2020, after first online publication: The P values in Table 3 have been transposed] The impact on SH versus LH scheme has been studied in previous reports as well, including HYCIS1. [5][6][7][8][9][10][11][12][13][14][15] In these reports, an SH proved to be associated with less or comparable nephrotoxicity. However, in these studies, many other factors differed between treatment groups as well, such as starting dose and administration rate of cisplatin, hydration fluid, electrolyte additives and diuretic use, which may have affected these results.…”

Section: Ta B L Ementioning

confidence: 99%

Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non–small‐cell lung cancer: A retrospective cohort study (HYCIS‐XL)

et al. 2020

View full text Add to dashboard Cite

What is known and objective Nephrotoxicity is a frequently occurring side effect of cisplatin, which may be reduced by applying ample hydration. The aim of this study was to determine whether there is a difference in decline in renal function due to cisplatin between a short hydration (SH) and long hydration scheme (LH). Methods A retrospective, observational, cohort study was conducted in two hospitals. Patients in one hospital received an SH scheme (SH group), whereas patients in the other hospital received an LH scheme (LH group). Other aspects of treatment and hydration were comparable between both patient groups. Consecutive patients (≥18 years) treated for non–small‐cell lung cancer with cisplatin‐pemetrexed with ≥1 cisplatin dose were included. Patients were excluded when serum creatinine at baseline was <40 μmol/L. Primary outcome was the difference in estimated glomerular filtration rate (eGFR) between baseline and after the last cisplatin cycle for the SH and LH patients, regardless of the number of administered cisplatin courses. Results Fifty patients were included in the SH and LH group. There were no significant differences in baseline characteristics between the two groups. None of the patients had renal failure at baseline. After two cisplatin cycles, the median differences between the baseline eGFR and the eGFR after the last cisplatin dose were 1 (−6 to 5) and −9 (−22 to −2) mL/min/1.73 m2 (interquartile range) for the SH and LH group, respectively (P = .000). Less patients completed the four cycles in the LH group (16%) compared to the SH group (64%), mainly because more LH patients were switched to another treatment and due to nephrotoxicity. However, the difference in eGFR remained statistically significant (P = .027). What is new and conclusion In this retrospective study, the SH scheme resulted in less decrease in renal function compared with the LH scheme, with a significant and clinically relevant difference. Additionally, more LH patients had to stop this effective treatment prematurely due to nephrotoxicity. Therefore, a short hydration scheme provides adequate and safe hydration, with a lower risk of nephrotoxic side effects and therefore better outcomes for patients and a reduction of healthcare costs.

show abstract

Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia

Zhang

Lin

Jin

et al. 2020

Breast Cancer Res Treat

View full text Add to dashboard Cite

Pre-hydration in cisplatin-based CCRT: Effects on tumour concentrations and treatment outcome

Cited by 6 publications

References 23 publications

Protective effect of food derived nutrients on cisplatin nephrotoxicity and its mechanism

Protective effect of food derived nutrients on cisplatin nephrotoxicity and its mechanism

Difference in decline in renal function due to cisplatin after a short or long hydration scheme in non–small‐cell lung cancer: A retrospective cohort study (HYCIS‐XL)

Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia

Contact Info

Product

Resources

About